The impact of bone histomorphometry, bone-related biomarkers, and FRAX® on fractures patients with predialysis CKD
Authors:
- Mariana Fernandes Diz LopesMLMariana Fernandes Diz Lopes
- Bernardo José Cardoso FernandesBFBernardo José Cardoso Fernandes
- Maria Teresa Almeida e Sousa Martins da RochaMRMaria Teresa Almeida e Sousa Martins da Rocha
- Maria Lúcia Carvalho CostaMCMaria Lúcia Carvalho Costa
- Ricardo de Morais Pereira NetoRNRicardo de Morais Pereira Neto
Open Access
- 1 December 2025
- journal article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20240276
Abstract
Introduction: Chronic kidney disease (CKD) patients are at increased risk of fracture. Whether the type of renal osteodystrophy (ROD) contributes to fracture risk is not currently established since bone biopsies are not frequently performed in clinical practice. We aimed to evaluate the association of ROD subtypes, bone biomarkers, and fracture risk assessed with the FRAX® tool with the occurrence of fractures in predialysis CKD patients. Methods: Retrospective study with patients followed between 2014–2023. Blood tests, including bone-related biomarkers (BRB), and bone biopsies were performed at the beginning of follow-up. Data from dual x-ray absorptiometry (DXA) scan and clinically evident fractures were obtained from medical registries. Radiographs of the thoracic/lumbar spine were evaluated to detect vertebral fractures, and the FRAX® index without bone mineral density (BMD) was calculated with the web-based tool. Results: Median follow-up time was 7.5 ± 3 years and 9.3% of the patients had a bone fracture, with an incidence of 12/1000 patient-year. Patients who had a fracture had higher phosphorus levels (4.1 mg/dL vs 3.5 mg/dL, p = 0.047). Histomorphometric subtypes and BRB were not associated with incidence of fractures nor with fracture risk assessed by FRAX®. There was a tendency for lower bone volume in the group with fractures (p = 0.057). FRAX® (without BMD), regardless of the inclusion of CKD as secondary osteoporosis, showed an overall good diagnostic accuracy for predicting fractures in predialysis CKD. Conclusion: ROD subtypes were not associated with incidence of fractures in these patients. The discriminative ability of FRAX in this population emphasizes its usefulness in CKD predialysis patients.Keywords
This publication has 26 references indexed in Scilit:
- Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled TrialClinical Journal of the American Society of Nephrology, 2017
- Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney diseaseJournal Of Nephrology, 2017
- The burden of fractures, vascular pathology and mortality in chronic kidney disease‐mineral and bone disordersNephrology, 2017
- High rates of death and hospitalization follow bone fracture among hemodialysis patientsKidney International, 2014
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature CommitteeJournal of Bone and Mineral Research, 2012
- Osteoporosis: impact on health and economicsNature Reviews Rheumatology, 2010
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2006
- Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysisNephrology Dialysis Transplantation, 2003
- The renal osteodystrophy pattern in Brazil and Uruguay: An overviewKidney International, 2003